Related Experiment Video
Updated: Mar 19, 2026
06:17
A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
12.7K
Benzbromarone, Quercetin, and Folic Acid Inhibit Amylin Aggregation
Laura C López1,2, Olga Varea3,4, Susanna Navarro5
1Departamento de Bioquímica y Biología Molecular y Celular, Facultad de Ciencias, Universidad de Zaragoza, Pedro Cerbuna 12, 50009 Zaragoza, Spain. lclopez@unizar.es.
International Journal of Molecular Sciences
|June 21, 2016
Summary
Researchers screened drugs to find inhibitors of human amylin (hIAPP) aggregation, a hallmark of type II diabetes. Quercetin showed potential in slowing aggregation and protecting pancreatic cells from damage.
Area of Science:
- Biochemistry
- Cell Biology
- Endocrinology
Background:
- Human amylin (hIAPP) aggregation in pancreatic β-cells is linked to type II diabetes.
- Abnormal hIAPP levels and amyloid formation contribute to β-cell apoptosis.
- Mechanisms underlying hIAPP-induced β-cell death require further investigation.
Purpose of the Study:
- Identify approved drugs that inhibit hIAPP aggregation.
- Investigate the therapeutic potential of identified compounds for type II diabetes.
- Explore the role of hIAPP aggregation in β-cell damage.
Main Methods:
- Screening of approved drug libraries for hIAPP aggregation inhibitors.
- In vitro assays: Thioflavin T binding, turbidimetry, Transmission Electron Microscopy.
- Cell culture models using pancreatic insulinoma cells exposed to hIAPP.
Main Results:
- Benzbromarone, quercetin, and folic acid demonstrated inhibition of hIAPP fiber formation in vitro.
- Quercetin provided partial protection to cultured pancreatic cells against hIAPP-induced cytotoxicity.
- Quercetin's protective effect may involve modulation of hIAPP aggregation and reduction of oxidative damage.
Conclusions:
- Approved drugs can inhibit hIAPP aggregation, offering tools for research and potential therapeutics.
- Quercetin emerges as a promising compound for mitigating hIAPP-related β-cell damage.
- Further research into quercetin's mechanism could lead to novel strategies for type II diabetes treatment.
More Related Videos
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
934
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
934
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
808
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
808
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
871
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
871
01:24Glucagon-like Receptor Agonists
1.2K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.2K
03:03Amyloid Fibrils
12.8K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
12.8K
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.5K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.5K